Massimo Maschio
Overview
Explore the profile of Massimo Maschio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Persoglia M, Maschio M, Di Cecco C, Barbi E
BMJ Case Rep
. 2025 Feb;
18(2).
PMID: 39956566
Gummatous tuberculosis, also known as metastatic tuberculous abscesses, represents an uncommon manifestation of cutaneous tuberculosis, marked by the presence of persistent subcutaneous abscesses. We report the case of a malnourished...
2.
Terlizzi V, Fevola C, Presti S, Claut L, Ambroni M, Calderazzo M, et al.
Pediatr Pulmonol
. 2025 Jan;
60(1):e27483.
PMID: 39812351
Background: Notwithstanding guidance from the European Cystic Fibrosis (CF) Society (ECFS) neonatal screening (NBS) working group, significant variation persists in the evaluation and management of Cystic Fibrosis Screen Positive, Inconclusive...
3.
Zuliani E, Canepari E, Pastore S, Neri F, Tesser A, Valencic E, et al.
Pediatr Pulmonol
. 2024 Nov;
60(1):e27423.
PMID: 39601531
No abstract available.
4.
Traunero A, Galletti A, Ghirardo S, Barbi E, Maschio M
Ital J Pediatr
. 2024 Jul;
50(1):138.
PMID: 39080772
Background: Elexacaftor-tezacaftor-ivacaftor (ETI) is a transmembrane conductance regulator modulator that significantly improves lung function in patients affected by cystic fibrosis (CF). This triple drug is currently not indicated in liver...
5.
Sutera M, Ghirardo S, Caiffa T, Maschio M, Bronzetti G, Barbi E
J Pediatr
. 2024 Jul;
274:114185.
PMID: 38986929
No abstract available.
6.
Ponis G, Decorti G, Barbi E, Stocco G, Maschio M
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38397035
Immunosuppression management in transplant recipients is a critical component of pharmacotherapy. This becomes particularly crucial when patients are exposed to multiple medications that may lead to pharmacological interactions, potentially compromising...
7.
Curatola A, Corona F, Squillaci D, Saccari A, Chiaretti A, Barbi E, et al.
Pediatr Pulmonol
. 2023 Nov;
59(3):592-599.
PMID: 38014586
Background: Cystic fibrosis (CF) is a genetic disease that causes progressive lung disease with major impact on the quality of life. Lung ultrasound (LUS) allows to assess the lung involvement...
8.
Traunero A, Peri F, Badina L, Amaddeo A, Zuliani E, Maschio M, et al.
Children (Basel)
. 2023 Sep;
10(9).
PMID: 37761496
Recipients of HSCT have a high risk of infective and non-infective pulmonary diseases. Most patients with pulmonary involvement present multiple pathogenetic mechanisms simultaneously with complex interactions. Therefore, it can be...
9.
Peri F, Amaddeo A, Badina L, Maschio M, Barbi E, Ghirardo S
Biomedicines
. 2023 May;
11(4).
PMID: 37189844
Asthma affects 10% of the worldwide population; about 5% of cases are severe with the need for target therapies such as biologics. All the biologics approved for asthma hit the...
10.
Ullmann N, Santamaria F, Allegorico A, Fainardi V, Borrelli M, Ferraro V, et al.
Pediatr Pulmonol
. 2023 Jan;
58(4):1127-1135.
PMID: 36588099
Introduction: There are no recent data on primary ciliary dyskinesia (PCD) distribution, diagnosis and treatment in Italy. Methods: A descriptive study based on a survey questionnaire. It consisted of three...